The implementation of VCE scoring in clinical practice could inform early pre-emptive therapeutic interventions, exclusively ...
16 小时
Nektar outlines $1B market opportunity for REZPEG in alopecia areata as Phase III plans advance
Get the latest Nektar Therapeutics Q3 2025 earnings call insights—financial updates, REZPEG trial milestones, and market opportunities.
The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈